Redeye comments on Carasent's Q3 2023 report, which was heavily influenced by lower consulting reven...
Redeye provides a short comment on this morning’s Q3 report from Ortoma.
Sales +2% and adj. EBITDA +16% vs. ABGSCe Operating cash flow 100% above ABGSCe Restructuring effort...
Redeye provides its initial comment on BONESUPPORT’s Q3 report.
NOI +0% and rec PTP +3% vs ABGSCe EC IFPM +33% q-o-q and +2% vs ABGSC 2024e Net LTV down to 27.
Förvaltningsresultat ökade med 14% på årsbasis och substansvärdet uppgick till 211 kronor.
Redeye provides its initial take on ADDvise’s Q3 2023 report, which came in broadly above our estima...
Redeye provides its initial comment on Sedana Medical’s Q3 report.
Redeye comments on Evolution’s Q3-results which came in slightly below our expectations owing to low...
Redeye states that the Q3 report beat its estimates on all fronts.
Redeye updates on Stillfront following its Q3-results which came in below our expectations.
Redeye’s view on the Q3 report. The organic growth trend turned positive with improvement in APAC an...
Redeye leaves a comment on yesterday’s news that Jesper Wiklund is stepping down as the CEO of Klari...
Redeye leaves a comment on the Q3 report published by Magle yesterday.
Redeye makes minimal estimate adjustments following the Q3’23 report, in which the reported figures ...
ESL Shipping volumes may have been weak in Q3. SSAB has already said that demand was weak in Q3 and ...
Redeye believes the Q2 report from Lagercrantz was strong, especially from a profit perspective, and...
Back to growth across geographies Strong momentum for Boråstapeter brand We raise the fair value ran...
Solid Q3 report – margins continue to improve We make small revisions to '24e-'25e EBIT Share is tra...
